Method of producing renal cells from differentiated cells

Patent metadata

Field	Value
Publication number	US-11046932-B2
Application number	US-201716072459-A
Country	US
Kind code	B2
Filing date	Jan 25, 2017
Priority date	Jan 25, 2016
Publication date	Jun 29, 2021
Grant date	Jun 29, 2021

Abstract

The present invention relates to a method for producing renal cells, comprising overexpressing Hnf1b and Pax8, and optionally Hnf4a and/or Emx2 in differentiated cells.

First claim

The invention claimed is:

1. A method of inducing the conversion of differentiated cells into induced renal tubular epithelial cells (iRECs), said method comprising the step of engineering said differentiated cells to overexpress Hnf1b and Pax8 by introducing into said differentiated cells one or more nucleic acids encoding the genes Hnf1b and Pax8 and overexpressing said genes so as to induce conversion of said differentiated cells into said iRECs, wherein said iRECs exhibit an mRNA-expression profile analogous to primary tubular cells, show morphological and functional features of kidney tubule epithelia, and are capable of integrating into kidney organoids and forming tubular structures in a decellularized kidney scaffold.

2. The method of claim 1 , wherein said differentiated cells are further engineered to overexpress Emx2 or Hnf4a.

3. The method of claim 1 , wherein said differentiated cells are further engineered to overexpress Emx2.

4. The method of claim 1 , wherein said differentiated cells are further engineered to overexpress Hnf4.

5. The method of claim 1 , wherein said differentiated cells are further engineered to overexpress Emx2 and Hnf4.

6. The method of claim 1 , wherein said differentiated cells are fibroblasts.

7. The method of claim 6 , wherein said fibroblasts are embryonic fibroblasts.

8. The method of claim 6 , wherein said fibroblasts are adult fibroblasts.

9. The method of claim 1 , wherein said differentiated cells are obtained from a non-human animal having a modification of a gene associated with a disorder affecting the kidney.

10. The method of claim 9 , wherein said disorder affecting the kidney is selected from the group consisting of conditions affecting the renal tubules, transport deficiencies, metabolic syndromes affecting renal tubules, ciliopathies, end stage renal disease, cystic kidney disease, polycystic kidney disease, CAKUT, renal cystic diseases, interstitial diseases, tumorous kidney diseases, renal tubular diseases, metabolic diseases, and nephrolithiasis.

11. The method of claim 9 , wherein said gene associated with a disorder affecting the kidney is Pkd1 or Pkd2.

12. The method of claim 6 , wherein said one or more nucleic acids are plasmids or vectors comprising a nucleotide sequence encoding the genes, operably linked to a promoter capable of inducing overexpression of the encoded genes.

13. The method of claim 2 , wherein said Emx2 comprises the nucleotide sequence as shown in SEQ ID NO:1 or a functional fragment thereof.

14. The method of claim 1 , wherein said Hnf1b comprises the nucleotide sequence as shown in SEQ ID NO:2 or a functional fragment thereof.

15. The method of claim 2 , wherein said Hnf4a comprises the nucleotide sequence as shown in SEQ ID NO:3 or a functional fragment thereof.

16. The method of claim 1 , wherein said Pax8 comprises the nucleotide sequence as shown in SEQ ID NO:4 or a functional fragment thereof.

17. The method of claim 1 , wherein said method further comprises the step of modifying in said differentiated cells at least one gene associated with a disorder affecting the kidney.

18. The method of claim 17 , wherein said step of modifying comprises disrupting said gene associated with a disorder affecting the kidney.

19. The method of claim 17 , wherein said disorder affecting the kidney is selected from the group consisting of conditions affecting the renal tubules, transport deficiencies, metabolic syndromes affecting renal tubules, ciliopathies, end stage renal disease, cystic kidney disease, polycystic kidney disease, CAKUT, Renal cystic diseases, interstitial diseases, tumorous kidney diseases, renal tubular diseases, metabolic diseases, and nephrolithiasis.

20. The method of claim 17 , wherein said gene associated with a disorder affecting the kidney is Pkd1 or Pkd2.

21. An induced renal tubular epithelial cell (iREC) obtained by the method of claim 1 .

22. The renal tubular epithelial cell of claim 21 , wherein said iREC has a modification in at least one gene associated with a disorder affecting the kidney.

23. The renal tubular epithelial cell of claim 22 , wherein said modification is a constitutive or conditional knockout of said gene.

24. The renal tubular epithelial of claim 22 , wherein said disorder affecting the kidney is selected from the group consisting of conditions affecting the renal tubules, transport deficiencies, metabolic syndromes affecting renal tubules, ciliopathies, end stage renal disease, cystic kidney disease, polycystic kidney disease, CAKUT, renal cystic diseases, interstitial diseases, tumorous kidney diseases, renal tubular diseases, metabolic diseases, and nephrolithiasis.

25. The renal tubular epithelial cell of claim 22 , wherein said gene associated with a disorder affecting the kidney is Pkd1 or Pkd2.

Assignees

• Univ Freiburg Albert Ludwigs

Inventors

• Lienkamp Soeren
• Kaminski Michael
• Arnold Sebastian
• Walz Gerd

Classifications

• C12N2506/1307

  from adult fibroblasts · CPC title

• A01K67/00

  Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals · CPC title

• G01N2500/10

  involving cells · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• C12N2501/60

  Transcription factors · CPC title